JP2022183120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022183120A5 JP2022183120A5 JP2022086267A JP2022086267A JP2022183120A5 JP 2022183120 A5 JP2022183120 A5 JP 2022183120A5 JP 2022086267 A JP2022086267 A JP 2022086267A JP 2022086267 A JP2022086267 A JP 2022086267A JP 2022183120 A5 JP2022183120 A5 JP 2022183120A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- same
- substituted
- different halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 114
- 125000005843 halogen group Chemical group 0.000 claims 105
- 125000003545 alkoxy group Chemical group 0.000 claims 97
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 47
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 40
- 125000002837 carbocyclic group Chemical group 0.000 claims 36
- 125000003118 aryl group Chemical group 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 125000004430 oxygen atom Chemical group O* 0.000 claims 18
- 208000008589 Obesity Diseases 0.000 claims 16
- 235000020824 obesity Nutrition 0.000 claims 16
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 206010020765 hypersomnia Diseases 0.000 claims 10
- 150000001721 carbon Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 201000003631 narcolepsy Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 208000011580 syndromic disease Diseases 0.000 claims 9
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000004434 sulfur atom Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 201000002832 Lewy body dementia Diseases 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 5
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000003003 spiro group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000019116 sleep disease Diseases 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims 3
- 208000007101 Muscle Cramp Diseases 0.000 claims 3
- 208000005392 Spasm Diseases 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000007958 sleep Effects 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- UOEJSBMYJAUDIQ-VQTJNVASSA-N C1(F)([C@@H]([C@@H](N2CCN(CC2)C(C)C)CCC1)NC(=S)N1CCC(CC1)(C=1N=C(ON=1)C1CC1)C)F Chemical compound C1(F)([C@@H]([C@@H](N2CCN(CC2)C(C)C)CCC1)NC(=S)N1CCC(CC1)(C=1N=C(ON=1)C1CC1)C)F UOEJSBMYJAUDIQ-VQTJNVASSA-N 0.000 claims 2
- HECYUOCZTUXXBA-WZYRSQIMSA-N CC1(CN(C)C(CC2)CCN2[C@@H](CCCC2(F)F)[C@H]2NC(N(CC2)CCC2(C)C2=NOC([C@H](C3)[C@H]3F)=N2)=O)CC1 Chemical compound CC1(CN(C)C(CC2)CCN2[C@@H](CCCC2(F)F)[C@H]2NC(N(CC2)CCC2(C)C2=NOC([C@H](C3)[C@H]3F)=N2)=O)CC1 HECYUOCZTUXXBA-WZYRSQIMSA-N 0.000 claims 2
- 206010010071 Coma Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 201000001883 cholelithiasis Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000008764 nerve damage Effects 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010068034 Adiposogenital dystrophy Diseases 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010052346 Brain contusion Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- YCRZYZBFNPPLHB-WNZNVHFWSA-N C1(F)([C@@H]([C@@H](N2C3CN(CC2CC3)C(C)C)CCC1)NC(=O)N1CCC(CC1)(C1=CC=C(C)C=C1)C)F Chemical compound C1(F)([C@@H]([C@@H](N2C3CN(CC2CC3)C(C)C)CCC1)NC(=O)N1CCC(CC1)(C1=CC=C(C)C=C1)C)F YCRZYZBFNPPLHB-WNZNVHFWSA-N 0.000 claims 1
- ZVEYZPLHQMAHRH-JSXRDJHFSA-N C1(F)([C@@H]([C@@H](N2CCN(CC2)C(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(ON=1)[C@@H]1C[C@@H]1C)C)F Chemical compound C1(F)([C@@H]([C@@H](N2CCN(CC2)C(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(ON=1)[C@@H]1C[C@@H]1C)C)F ZVEYZPLHQMAHRH-JSXRDJHFSA-N 0.000 claims 1
- CVWLWTJUEYHULC-LILSUDLASA-N C1(F)([C@@H]([C@@H](N2CC[C@@H](C2)N(CC2CC2)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@@H]2C[C@@H]2F)ON=1)C)F Chemical compound C1(F)([C@@H]([C@@H](N2CC[C@@H](C2)N(CC2CC2)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@@H]2C[C@@H]2F)ON=1)C)F CVWLWTJUEYHULC-LILSUDLASA-N 0.000 claims 1
- LJVVJQJIPPBGCJ-HGJUEJDCSA-N C1(F)([C@@H]([C@@H](N2C[C@H](CC2)N(C)C(C)C)CCC1)NC(=O)N1CCC(C=2N=C([C@@H]3C[C@@H]3F)ON=2)(C)CC1)F Chemical compound C1(F)([C@@H]([C@@H](N2C[C@H](CC2)N(C)C(C)C)CCC1)NC(=O)N1CCC(C=2N=C([C@@H]3C[C@@H]3F)ON=2)(C)CC1)F LJVVJQJIPPBGCJ-HGJUEJDCSA-N 0.000 claims 1
- WLSHXUSVYGRIJH-IVAOSVALSA-N C1(F)([C@@H]([C@@H](OC2CCN(CC2)C(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@@H]2C[C@@H]2F)ON=1)C)F Chemical compound C1(F)([C@@H]([C@@H](OC2CCN(CC2)C(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@@H]2C[C@@H]2F)ON=1)C)F WLSHXUSVYGRIJH-IVAOSVALSA-N 0.000 claims 1
- CHTUQLNNQUJXDI-SLFFLAALSA-N C1(F)([C@@H]([C@@H](O[C@@H]2CN(CC2)C(C)C)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F Chemical compound C1(F)([C@@H]([C@@H](O[C@@H]2CN(CC2)C(C)C)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F CHTUQLNNQUJXDI-SLFFLAALSA-N 0.000 claims 1
- VCLKVFHTBUMEJP-HGJUEJDCSA-N C1(F)([C@@H]([C@@H](O[C@@H]2CN(CC2)CC(C)(C)C)CCC1)NC(=O)N1CCC(C=2N=C([C@@H]3C[C@@H]3F)ON=2)(C)CC1)F Chemical compound C1(F)([C@@H]([C@@H](O[C@@H]2CN(CC2)CC(C)(C)C)CCC1)NC(=O)N1CCC(C=2N=C([C@@H]3C[C@@H]3F)ON=2)(C)CC1)F VCLKVFHTBUMEJP-HGJUEJDCSA-N 0.000 claims 1
- USHIPFCUEIQEGC-HGJUEJDCSA-N C1(F)([C@@H]([C@@H](O[C@@H]2CN(CC2)CC2(C)CC2)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(ON=1)[C@@H]1C[C@@H]1F)C)F Chemical compound C1(F)([C@@H]([C@@H](O[C@@H]2CN(CC2)CC2(C)CC2)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(ON=1)[C@@H]1C[C@@H]1F)C)F USHIPFCUEIQEGC-HGJUEJDCSA-N 0.000 claims 1
- PMARKAUKFSFVFR-TZRRMPRUSA-N C1(F)([C@@H]([C@@H](O[C@H]2CN(CC2)C(C)C)CCC1)NC(=O)N1CCC(C2=CC=C(C)C=C2)(C)CC1)F Chemical compound C1(F)([C@@H]([C@@H](O[C@H]2CN(CC2)C(C)C)CCC1)NC(=O)N1CCC(C2=CC=C(C)C=C2)(C)CC1)F PMARKAUKFSFVFR-TZRRMPRUSA-N 0.000 claims 1
- TZWUDTFBNCDNSN-LWYYNNOASA-N C1(F)([C@@H]([C@@H](O[C@H]2CN(C[C@@H]2F)C(C)C)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F Chemical compound C1(F)([C@@H]([C@@H](O[C@H]2CN(C[C@@H]2F)C(C)C)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F TZWUDTFBNCDNSN-LWYYNNOASA-N 0.000 claims 1
- GLWSLJBLEFALAL-PCCBWWKXSA-N CC(C)(C)CN(CC1)C[C@H]1O[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O Chemical compound CC(C)(C)CN(CC1)C[C@H]1O[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O GLWSLJBLEFALAL-PCCBWWKXSA-N 0.000 claims 1
- VDYZOESVPZUTLJ-LILSUDLASA-N CC(C)CN(C)[C@H]1CCN(C1)[C@H]2CCCC([C@@H]2NC(=O)N3CCC(CC3)(C)C4=NOC(=N4)[C@@H]5C[C@@H]5F)(F)F Chemical compound CC(C)CN(C)[C@H]1CCN(C1)[C@H]2CCCC([C@@H]2NC(=O)N3CCC(CC3)(C)C4=NOC(=N4)[C@@H]5C[C@@H]5F)(F)F VDYZOESVPZUTLJ-LILSUDLASA-N 0.000 claims 1
- SVFWYTMXDYKYKO-PCCBWWKXSA-N CC(C)CN1CC[C@@H](C1)O[C@H]2CCCC([C@@H]2NC(=O)N3CCC(CC3)(C)C4=NOC(=N4)C5CC5)(F)F Chemical compound CC(C)CN1CC[C@@H](C1)O[C@H]2CCCC([C@@H]2NC(=O)N3CCC(CC3)(C)C4=NOC(=N4)C5CC5)(F)F SVFWYTMXDYKYKO-PCCBWWKXSA-N 0.000 claims 1
- RJSHSSODFIVFPS-CLAROIROSA-N CC(C)N(C)C(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O Chemical compound CC(C)N(C)C(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O RJSHSSODFIVFPS-CLAROIROSA-N 0.000 claims 1
- KLKDGVADFFJMII-NZQKXSOJSA-N CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=C1)=O Chemical compound CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=C1)=O KLKDGVADFFJMII-NZQKXSOJSA-N 0.000 claims 1
- NESCNZHCKMFVFR-VQTJNVASSA-N CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O Chemical compound CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O NESCNZHCKMFVFR-VQTJNVASSA-N 0.000 claims 1
- WAHDJZMTTZYAST-LEWJYISDSA-N CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CCC2)=N1)=O Chemical compound CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CCC2)=N1)=O WAHDJZMTTZYAST-LEWJYISDSA-N 0.000 claims 1
- ZVEYZPLHQMAHRH-IVAOSVALSA-N CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@@H]2[C@H](C)C2)=N1)=O Chemical compound CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@@H]2[C@H](C)C2)=N1)=O ZVEYZPLHQMAHRH-IVAOSVALSA-N 0.000 claims 1
- FWMZZWSFGFFHBO-FUMNGEBKSA-N CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O Chemical compound CC(C)N(CC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O FWMZZWSFGFFHBO-FUMNGEBKSA-N 0.000 claims 1
- NGCOOSNNFZJLFW-HKBOAZHASA-N CC(C)N(CC1)CCN1[C@@H](CCC[C@H]1F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O Chemical compound CC(C)N(CC1)CCN1[C@@H](CCC[C@H]1F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O NGCOOSNNFZJLFW-HKBOAZHASA-N 0.000 claims 1
- KLKDGVADFFJMII-OFNKIYASSA-N CC(C)N(CC1)CCN1[C@H](CCCC1(F)F)[C@@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=C1)=O Chemical compound CC(C)N(CC1)CCN1[C@H](CCCC1(F)F)[C@@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=C1)=O KLKDGVADFFJMII-OFNKIYASSA-N 0.000 claims 1
- NESCNZHCKMFVFR-UXHICEINSA-N CC(C)N(CC1)CCN1[C@H](CCCC1(F)F)[C@@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O Chemical compound CC(C)N(CC1)CCN1[C@H](CCCC1(F)F)[C@@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O NESCNZHCKMFVFR-UXHICEINSA-N 0.000 claims 1
- FWMZZWSFGFFHBO-NMLBUPMWSA-N CC(C)N(CC1)CCN1[C@H](CCCC1(F)F)[C@@H]1NC(N(CC1)CCC1(C)C1=NOC([C@@H](C2)[C@@H]2F)=N1)=O Chemical compound CC(C)N(CC1)CCN1[C@H](CCCC1(F)F)[C@@H]1NC(N(CC1)CCC1(C)C1=NOC([C@@H](C2)[C@@H]2F)=N1)=O FWMZZWSFGFFHBO-NMLBUPMWSA-N 0.000 claims 1
- IWDSBAGRQVFKMC-CRSSMBPESA-N CC(C)N(CC1)C[C@@H](C)N1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O Chemical compound CC(C)N(CC1)C[C@@H](C)N1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O IWDSBAGRQVFKMC-CRSSMBPESA-N 0.000 claims 1
- GYTPCNSYXQTILI-SWBPCFCJSA-N CC(C)N(CC1)C[C@@H]1O[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O Chemical compound CC(C)N(CC1)C[C@@H]1O[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O GYTPCNSYXQTILI-SWBPCFCJSA-N 0.000 claims 1
- IWDSBAGRQVFKMC-HGJUEJDCSA-N CC(C)N(CC1)C[C@H](C)N1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O Chemical compound CC(C)N(CC1)C[C@H](C)N1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O IWDSBAGRQVFKMC-HGJUEJDCSA-N 0.000 claims 1
- JFFINXHSJLPKOD-HGJUEJDCSA-N CC(C)N(CC1)C[C@H]1N(C)[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O Chemical compound CC(C)N(CC1)C[C@H]1N(C)[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O JFFINXHSJLPKOD-HGJUEJDCSA-N 0.000 claims 1
- IGMQFTXINFOOAN-LJDSDSDDSA-N CC(C)N(CC1)C[C@H]1N[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O Chemical compound CC(C)N(CC1)C[C@H]1N[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O IGMQFTXINFOOAN-LJDSDSDDSA-N 0.000 claims 1
- GYTPCNSYXQTILI-LJDSDSDDSA-N CC(C)N(CC1)C[C@H]1O[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O Chemical compound CC(C)N(CC1)C[C@H]1O[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O GYTPCNSYXQTILI-LJDSDSDDSA-N 0.000 claims 1
- OEMYUUCTTUHIBO-JRSUCEMESA-N CC(C)N(CC1)C[C@H]1O[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H]2[C@@H](C)C2)=N1)=O Chemical compound CC(C)N(CC1)C[C@H]1O[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H]2[C@@H](C)C2)=N1)=O OEMYUUCTTUHIBO-JRSUCEMESA-N 0.000 claims 1
- OCFMCSDIPSBEEN-BBLPBDBVSA-N CC(C)N(CC1CC2)CC2N1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=C1)=O Chemical compound CC(C)N(CC1CC2)CC2N1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=C1)=O OCFMCSDIPSBEEN-BBLPBDBVSA-N 0.000 claims 1
- IHJCKPGPRQYTBJ-QZNJRLLKSA-N CC(C)N(CC1CC2)CC2N1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O Chemical compound CC(C)N(CC1CC2)CC2N1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC(C2CC2)=N1)=O IHJCKPGPRQYTBJ-QZNJRLLKSA-N 0.000 claims 1
- RQJWUBWJBAYZOK-IVAOSVALSA-N CC(C)N(CCC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O Chemical compound CC(C)N(CCC1)CCN1[C@@H](CCCC1(F)F)[C@H]1NC(N(CC1)CCC1(C)C1=NOC([C@H](C2)[C@H]2F)=N1)=O RQJWUBWJBAYZOK-IVAOSVALSA-N 0.000 claims 1
- CHTUQLNNQUJXDI-HSALFYBXSA-N CC(C)N1CC[C@H](C1)O[C@H]2CCCC([C@@H]2NC(=O)N3CCC(CC3)(C)C4=NOC(=N4)C5CC5)(F)F Chemical compound CC(C)N1CC[C@H](C1)O[C@H]2CCCC([C@@H]2NC(=O)N3CCC(CC3)(C)C4=NOC(=N4)C5CC5)(F)F CHTUQLNNQUJXDI-HSALFYBXSA-N 0.000 claims 1
- JHYVYJOSUAGLAY-WZYRSQIMSA-N CC(CC1)(CCN1C(N[C@H]([C@H](CCC1)N(CC2)CCC2N(C)C2CCC2)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 Chemical compound CC(CC1)(CCN1C(N[C@H]([C@H](CCC1)N(CC2)CCC2N(C)C2CCC2)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 JHYVYJOSUAGLAY-WZYRSQIMSA-N 0.000 claims 1
- ZOHMZJHUVAXZFH-CLAROIROSA-N CC(CC1)(CCN1C(N[C@H]([C@H](CCC1)N(CC2)CCC2N(C)CC2(CC2)F)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 Chemical compound CC(CC1)(CCN1C(N[C@H]([C@H](CCC1)N(CC2)CCC2N(C)CC2(CC2)F)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 ZOHMZJHUVAXZFH-CLAROIROSA-N 0.000 claims 1
- QDPNISHWRDSFJA-WZYRSQIMSA-N CC(CC1)(CCN1C(N[C@H]([C@H](CCC1)N(CC2)CCC2N(C)CC2CC2)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 Chemical compound CC(CC1)(CCN1C(N[C@H]([C@H](CCC1)N(CC2)CCC2N(C)CC2CC2)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 QDPNISHWRDSFJA-WZYRSQIMSA-N 0.000 claims 1
- IVHHSRSGMIVZOG-LJDSDSDDSA-N CC(CC1)(CCN1C(N[C@H]([C@H](CCC1)O[C@@H]2CN(CC3(CC3)F)CC2)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 Chemical compound CC(CC1)(CCN1C(N[C@H]([C@H](CCC1)O[C@@H]2CN(CC3(CC3)F)CC2)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 IVHHSRSGMIVZOG-LJDSDSDDSA-N 0.000 claims 1
- OFSKMJJWPOWGKF-FDFHNCONSA-N CC1(CCN(CC1)C(=O)N[C@@H]2[C@H](CCCC2(F)F)N3CC[C@@H](C3)N(C)CC4CC4)C5=NOC(=N5)C6CC6 Chemical compound CC1(CCN(CC1)C(=O)N[C@@H]2[C@H](CCCC2(F)F)N3CC[C@@H](C3)N(C)CC4CC4)C5=NOC(=N5)C6CC6 OFSKMJJWPOWGKF-FDFHNCONSA-N 0.000 claims 1
- IGVDWJXMMFZTNJ-HGJUEJDCSA-N CC1(CCN(CC1)C(=O)N[C@@H]2[C@H](CCCC2(F)F)O[C@H]3CCN(C3)CC4CC4)C5=NOC(=N5)[C@@H]6C[C@@H]6F Chemical compound CC1(CCN(CC1)C(=O)N[C@@H]2[C@H](CCCC2(F)F)O[C@H]3CCN(C3)CC4CC4)C5=NOC(=N5)[C@@H]6C[C@@H]6F IGVDWJXMMFZTNJ-HGJUEJDCSA-N 0.000 claims 1
- BDRNNHOXSOLYLJ-HGJUEJDCSA-N CCC(CC1)(CCN1C(N[C@H]([C@H](CCC1)O[C@@H](CC2)CN2C(C)C)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 Chemical compound CCC(CC1)(CCN1C(N[C@H]([C@H](CCC1)O[C@@H](CC2)CN2C(C)C)C1(F)F)=O)C1=NOC([C@H](C2)[C@H]2F)=N1 BDRNNHOXSOLYLJ-HGJUEJDCSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000001573 Cataplexy Diseases 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000027691 Conduct disease Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000008967 Enuresis Diseases 0.000 claims 1
- HHDQTRQIMYNRMX-HGJUEJDCSA-N FC1(F)[C@@H]([C@@H](O[C@@H]2CN(CC2)CC(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@H]2[C@H](C2)F)ON=1)C Chemical compound FC1(F)[C@@H]([C@@H](O[C@@H]2CN(CC2)CC(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@H]2[C@H](C2)F)ON=1)C HHDQTRQIMYNRMX-HGJUEJDCSA-N 0.000 claims 1
- CMQLXYQRWMIOHO-PCCBWWKXSA-N FC1([C@@H]([C@@H](N2CC[C@@H](C2)N(C(C)C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(C2CC2)ON=1)C)F Chemical compound FC1([C@@H]([C@@H](N2CC[C@@H](C2)N(C(C)C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(C2CC2)ON=1)C)F CMQLXYQRWMIOHO-PCCBWWKXSA-N 0.000 claims 1
- LJVVJQJIPPBGCJ-CRSSMBPESA-N FC1([C@@H]([C@@H](N2CC[C@@H](N(C(C)C)C)C2)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(ON=1)[C@@H]1C[C@@H]1F)C)F Chemical compound FC1([C@@H]([C@@H](N2CC[C@@H](N(C(C)C)C)C2)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(ON=1)[C@@H]1C[C@@H]1F)C)F LJVVJQJIPPBGCJ-CRSSMBPESA-N 0.000 claims 1
- IAWILGDDMNBSSX-HGJUEJDCSA-N FC1([C@@H]([C@@H](N2C[C@H](CC2)N(C)C2CC2)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@H]2[C@H](C2)F)ON=1)C)F Chemical compound FC1([C@@H]([C@@H](N2C[C@H](CC2)N(C)C2CC2)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@H]2[C@H](C2)F)ON=1)C)F IAWILGDDMNBSSX-HGJUEJDCSA-N 0.000 claims 1
- JEDXBFKEYKLMOQ-IPMKNSEASA-N FC1([C@@H]([C@@H](O[C@@H]2CN(CC2(F)F)C(C)C)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F Chemical compound FC1([C@@H]([C@@H](O[C@@H]2CN(CC2(F)F)C(C)C)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F JEDXBFKEYKLMOQ-IPMKNSEASA-N 0.000 claims 1
- GJYAXRJJWFCHMB-PCCBWWKXSA-N FC1([C@@H]([C@@H](O[C@@H]2CN(CC2)C(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(C2CCC2)ON=1)C)F Chemical compound FC1([C@@H]([C@@H](O[C@@H]2CN(CC2)C(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C(C2CCC2)ON=1)C)F GJYAXRJJWFCHMB-PCCBWWKXSA-N 0.000 claims 1
- NMXYGEAMFVJSCT-LJDSDSDDSA-N FC1([C@@H]([C@@H](O[C@@H]2CN(CC2)CC(F)(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@H]2[C@H](C2)F)ON=1)C)F Chemical compound FC1([C@@H]([C@@H](O[C@@H]2CN(CC2)CC(F)(C)C)CCC1)NC(=O)N1CCC(CC1)(C=1N=C([C@H]2[C@H](C2)F)ON=1)C)F NMXYGEAMFVJSCT-LJDSDSDDSA-N 0.000 claims 1
- NIWBBDLWDNDNMO-PCCBWWKXSA-N FC1([C@@H]([C@@H](O[C@@H]2CN(CC2)CC2(C)CC2)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F Chemical compound FC1([C@@H]([C@@H](O[C@@H]2CN(CC2)CC2(C)CC2)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F NIWBBDLWDNDNMO-PCCBWWKXSA-N 0.000 claims 1
- DGLWOJPOSMWSSJ-PCCBWWKXSA-N FC1([C@@H]([C@@H](O[C@@H]2CN(CC2)CC2CC2)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F Chemical compound FC1([C@@H]([C@@H](O[C@@H]2CN(CC2)CC2CC2)CCC1)NC(=O)N1CCC(C=2N=C(C3CC3)ON=2)(C)CC1)F DGLWOJPOSMWSSJ-PCCBWWKXSA-N 0.000 claims 1
- 208000010235 Food Addiction Diseases 0.000 claims 1
- 201000001498 Froelich syndrome Diseases 0.000 claims 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000016905 Hashimoto encephalopathy Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 206010053712 Hypersomnia-bulimia syndrome Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 208000028482 Hypothalamic disease Diseases 0.000 claims 1
- 206010021133 Hypoventilation Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 201000008178 Kleine-Levin syndrome Diseases 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 201000002983 Mobius syndrome Diseases 0.000 claims 1
- 208000034167 Moebius syndrome Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 1
- 208000000224 Night Terrors Diseases 0.000 claims 1
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 108050000742 Orexin Receptor Proteins 0.000 claims 1
- 102000008834 Orexin receptor Human genes 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000007683 Pediatric Obesity Diseases 0.000 claims 1
- 206010035004 Pickwickian syndrome Diseases 0.000 claims 1
- 206010036049 Polycystic ovaries Diseases 0.000 claims 1
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000000810 Separation Anxiety Diseases 0.000 claims 1
- 208000020221 Short stature Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041010 Sleep terror Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010041347 Somnambulism Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010042434 Sudden death Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 208000003443 Unconsciousness Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047513 Vision blurred Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- IMTFFEMCZWFYKC-YMQHIKHWSA-N [C@H]1(F)[C@@H](NC(=O)N2CCC(C=3N=C([C@@H]4C[C@@H]4F)ON=3)(C)CC2)[C@@H](CCC1)N1CCN(CC1)C(C)C Chemical compound [C@H]1(F)[C@@H](NC(=O)N2CCC(C=3N=C([C@@H]4C[C@@H]4F)ON=3)(C)CC2)[C@@H](CCC1)N1CCN(CC1)C(C)C IMTFFEMCZWFYKC-YMQHIKHWSA-N 0.000 claims 1
- IMTFFEMCZWFYKC-SYAJIYQZSA-N [C@H]1([C@@H](N2CCN(CC2)C(C)C)CCC[C@@H]1F)NC(=O)N1CCC(C=2N=C([C@@H]3C[C@@H]3F)ON=2)(C)CC1 Chemical compound [C@H]1([C@@H](N2CCN(CC2)C(C)C)CCC[C@@H]1F)NC(=O)N1CCC(C=2N=C([C@@H]3C[C@@H]3F)ON=2)(C)CC1 IMTFFEMCZWFYKC-SYAJIYQZSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 230000002566 clonic effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 230000035558 fertility Effects 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 230000000910 hyperinsulinemic effect Effects 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000010325 limbic encephalitis Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 206010029410 night sweats Diseases 0.000 claims 1
- 230000036565 night sweats Effects 0.000 claims 1
- 230000000422 nocturnal effect Effects 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims 1
- 208000017443 reproductive system disease Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000025874 separation anxiety disease Diseases 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- 230000003860 sleep quality Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021088030 | 2021-05-26 | ||
| JP2021088030 | 2021-05-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022183120A JP2022183120A (ja) | 2022-12-08 |
| JP2022183120A5 true JP2022183120A5 (cg-RX-API-DMAC7.html) | 2023-12-01 |
| JP7668768B2 JP7668768B2 (ja) | 2025-04-25 |
Family
ID=84328346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022086267A Active JP7668768B2 (ja) | 2021-05-26 | 2022-05-26 | シクロアルキルウレア誘導体を含有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7668768B2 (cg-RX-API-DMAC7.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010155827A (ja) | 2008-12-04 | 2010-07-15 | Takeda Chem Ind Ltd | スピロ環化合物 |
| ES2570177T3 (es) | 2010-08-10 | 2016-05-17 | Astellas Pharma Inc | Compuesto heterocíclico |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| EP3029024A1 (en) * | 2014-12-02 | 2016-06-08 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| SG11201806429PA (en) | 2016-02-04 | 2018-08-30 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
-
2022
- 2022-05-26 JP JP2022086267A patent/JP7668768B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7739180B2 (ja) | シクロアルキルウレア誘導体 | |
| US11459327B1 (en) | Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof | |
| JPWO2022250108A5 (cg-RX-API-DMAC7.html) | ||
| JP5690823B2 (ja) | Jak受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物 | |
| AU2015251030B2 (en) | Novel disubstituted 1, 2, 4-triazine compound | |
| CN101679287B (zh) | 烟碱型乙酰胆碱受体调节剂 | |
| JP7088965B2 (ja) | アリール複素環ピペリジノンホルミルペプチド2受容体およびホルミルペプチド1受容体アゴニスト | |
| JP2010522721A (ja) | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 | |
| JP7098663B2 (ja) | ピペリジノンホルミルペプチド2受容体アゴニスト | |
| JP2010505794A (ja) | カリウムチャネル調節剤として有用なインダゾリル誘導体 | |
| WO2022250108A1 (ja) | フェニルウレア誘導体 | |
| CN1335850A (zh) | 化合物 | |
| WO2000026186A1 (en) | Pyrrolidine compounds and medicinal utilization thereof | |
| TW200528440A (en) | 2-cyanopyrrolidinecarboxamide compound | |
| JP2011517443A5 (cg-RX-API-DMAC7.html) | ||
| KR20090071662A (ko) | 헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도 | |
| JP2017534569A (ja) | PI3K、mTOR阻害薬としての縮合キノリン化合物 | |
| RU2006105782A (ru) | Производные 1-сульфонилиндола, их получение и их применение в качестве лигандов 5-нт-6 | |
| JP6393749B2 (ja) | Cxcr7受容体調節剤 | |
| JPWO2023204291A5 (cg-RX-API-DMAC7.html) | ||
| JP2010527967A (ja) | 新規な2,3−ジアミノキナゾリノン誘導体及びそれらの医療での使用 | |
| US20120238547A1 (en) | 2, 3, 6 - triamino substituted pyridines as kv7 (kcnq) channel modulators | |
| RU2024134350A (ru) | Бициклоаминкарбоксамидное производное | |
| JP2011506391A (ja) | カリウムチャネル活性化因子として有用な、新規の2−エチル−メチル−アミノ−3−アミド−6−アミノ−ピリジン誘導体 | |
| CN119948015A (zh) | 新型磺胺及其作为神经保护剂和/或神经修复剂的用途 |